StockNews.AI
IMMP
StockNews.AI
21 days

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

1. EFTISARC-NEO Phase II trial relevant for Immutep accepted for oral presentation. 2. Trial evaluates eftilagimod alpha in soft tissue sarcoma alongside KEYTRUDA. 3. Soft tissue sarcoma has high unmet medical need, affecting 13,520 patients in 2025. 4. Oral presentation scheduled for November 13, 2025, at CTOS Annual Meeting. 5. Immutep's LAG-3 research shows potential advancements in cancer treatments.

5m saved
Insight
Article

FAQ

Why Bullish?

The acceptance for presentation indicates strong clinical data and investor interest, similar to past biotech successes like Kite Pharma after notable trial presentations.

How important is it?

The upcoming presentation highlights key data likely to attract investor attention and create market momentum.

Why Long Term?

The trial’s results may positively influence Immutep’s stock value over the long-term, similar to how successful Phase III results have historically propelled biotech stocks.

Related Companies

MRK
September 08, 2025 08:00 ET  | Source: Immutep Limited Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting  SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida. EFTISARC-NEO is the first study to evaluate eftilagimod alpha (efti) in a neoadjuvant setting (prior to surgery) administered in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) for patients with soft tissue sarcoma (STS). Presentation DetailsTitle:Primary endpoint and translational correlates from EFTISARC-NEO: phase II trial of neoadjuvant eftilagimod alpha (efti), pembrolizumab, and radiotherapy in patients with resectable soft tissue sarcomaSession:Immunotherapy & Cell Therapy in Sarcoma: Emerging FrontiersPresenter:Pawel Sobczuk, M.D., Ph.D., Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of OncologyDate:Thursday, 13 November 2025, 1:30 PM – 3:00 PM ET         Format:Oral Presentation   STS is an orphan disease with high unmet medical need and a poor prognosis for patients. The incidence of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer Society.1 EFTISARC-NEO is is being conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. The study is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. For more information on the trial visit clinicaltrials.gov (NCT06128863). The presentation slides will be available on the Posters & Publications section of Immutep’s website after the presentation at CTOS 2025. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. 1. American Cancer Society statistics: https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; eleanor.pearson@sodali.com U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com

Related News